InMed Pharmaceuticals (INM) Gross Profit (2021 - 2025)

InMed Pharmaceuticals has reported Gross Profit for 5 years, with the latest figure at $184194.0 in Q4 2025.

• For the quarter ending Q4 2025, Gross Profit fell 60.04% year-over-year to $184194.0; the trailing twelve-month figure through Dec 2025 stood at $1.3 million (down 21.65% YoY), and the FY2025 full-year result was $1.7 million, up 55.02% from the prior year.
• Gross Profit for Q4 2025 stood at $184194.0, down from $403159.0 in the prior quarter.
• The five-year high for Gross Profit was $1.6 million in Q2 2023, with the low at -$491018.0 in Q3 2022.
• Historically, Gross Profit has averaged $314202.0 across 5 years, with a median of $249714.0 in 2022.
• The largest YoY upside for Gross Profit was 2222.82% in 2024 against a maximum downside of 70.32% in 2024.
• InMed Pharmaceuticals' Gross Profit stood at $111555.0 in 2021, then grew by 17.58% to $131163.0 in 2022, then jumped by 147.13% to $324142.0 in 2023, then surged by 42.19% to $460894.0 in 2024, then sank by 60.04% to $184194.0 in 2025.
• The last three Gross Profit figures came in at $184194.0 (Q4 2025), $403159.0 (Q3 2025), and $576654.0 (Q2 2025), per Business Quant data.